t
Sareum Holdings PLC announced on 4 July 2025 that Oberon Capital has been appointed as the Company's sole broker. This appointment takes immediate effect.
| Date | 4 Jul 2025 |
| Time | 07:00:01 |
| Category | Miscellaneous |
| ID | 6776P |
Sareum Holdings PLC
("Sareum" or the "Company")
Appointment of Sole Broker
Cambridge, UK, 4 July 2025 - Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, announces that Oberon Capital has been appointed as the Company's sole broker with immediate effect.
- ENDS-
For further information, please contact:
|
Sareum Holdings plc Stephen Parker, Executive Chairman |
01223 497700 |
|
Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
|
020 7409 3494 |
|
Oberon Capital (Broker) Mike Seabrook / Nick Lovering
|
020 3179 5300 |
|
ICR Healthcare (Financial PR) Jessica Hodgson / Davide Salvi |
020 3709 5700 |
About Sareum
Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with a planned initial focus on psoriasis.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.
The Company has recently acquired the license for SRA737, a clinical-stage Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com